Zimmer Biomet Holdings, Inc. (ZBH) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Zimmer Biomet Holdings, Inc. (ZBH) stock forecast summary
Our AI ranks Zimmer Biomet Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Zimmer Biomet Holdings, Inc. is a large-cap company with a market capitalization of $18.12B. It ranks number 3 by market capitalization among the 27 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.
For ZBH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 26.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ZBH included.
Follow ZBH freeZBH price chart and AI forecast
How ZBH ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Zimmer Biomet Holdings, Inc. (ZBH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | ZBH | Rank |
|---|---|---|
| Market Cap | $18.12B | 3/27 |
| P/E Ratio | 18.88x | 6/9 |
| P/B Ratio | 1.44x | 13/22 |
| Dividend Yield | 1.04% | – |
| EPS | $5.03 | – |
| Book Value/Share | $66.18 | – |
| Revenue/Share | $44.61 | – |
| FCF/Share | $7.98 | – |
Profitability & Margins
| Metric | ZBH | Rank |
|---|---|---|
| ROE | 6.4% | 7/19 |
| ROA | 3.5% | 7/19 |
| ROIC | 6.1% | 10/22 |
| Gross Margin | 69.9% | 4/20 |
| Operating Margin | 14.2% | 4/21 |
| Net Margin | 9.5% | 5/17 |
| EBT Margin | 11.0% | 5/21 |
| Tax Rate | 13.6% | – |
Financial Health
| Metric | ZBH | Rank |
|---|---|---|
| Current Ratio | 1.69x | 22/25 |
| Quick Ratio | 0.94x | 21/22 |
| D/E Ratio | 0.81x | 11/24 |
| Financial Leverage | 1.81x | 11/24 |
| Working Capital | $2.08B | 3/25 |
Cash Flow
| Metric | ZBH | Rank |
|---|---|---|
| Operating Cash Flow | $1.74B | 3/25 |
| Free Cash Flow | $1.52B | 2/16 |
| Capital Spending | -$220M | 15/16 |
| OCF Growth YoY | 4.8% | 8/10 |
| FCF Growth YoY | 3.4% | 6/7 |
| FCF/Sales | 17.9% | 3/16 |
| CapEx/Sales | 2.6% | 7/16 |
Operational Efficiency
| Metric | ZBH | Rank |
|---|---|---|
| Asset Turnover | 0.37x | 15/18 |
| Receivables Turnover | 4.8x | 12/17 |
| Inventory Turnover | 1.1x | 17/22 |
| Fixed Assets Turnover | 3.8x | 12/19 |
| Days Sales Outstanding | 76 days | 6/17 |
| Days Inventory | 323 days | 6/22 |
| Payables Period | 50 days | 12/19 |
| Cash Conversion Cycle | 349 days | 2/15 |
Income Statement
| Metric | ZBH | Rank |
|---|---|---|
| Total Revenue | $8.51B | 2/19 |
| Operating Income | $1.21B | 3/25 |
| Net Income | $807M | 2/19 |
| R&D Expense | $443M | 3/22 |
| SG&A Expense | $3.43B | 2/22 |
| Cost of Goods Sold | $2.56B | 4/22 |
Dividend & Shareholder Information
| Metric | ZBH | Rank |
|---|---|---|
| Dividends Per Share | $0.99 | – |
| Payout Ratio | 19.7% | – |
| Shares Outstanding | 191M | – |
| Net Income Growth | -2.0% | 5/7 |
| EPS Growth | 25.1% | 1/8 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $5.10B | 22.4% of assets |
| Cash & Short-term Investments | $410M | 1.8% of assets |
| Accounts Receivable | $1.77B | 7.8% of assets |
| Inventory | $2.27B | 10.0% of assets |
| Total Liabilities | $10.17B | 44.6% of assets |
| Short-term Debt | $2.66B | 11.7% of assets |
ZBH quarterly financials and insider trading
Zimmer Biomet Holdings, Inc. (ZBH) industry peers
Companies classified under the same SEC industry code as Zimmer Biomet Holdings, Inc. (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ZBH Zimmer Biomet Holdings, Inc. | ▼ | $18.12B |
| ISRG Intuitive Surgical Inc | ▼ | $150.74B |
| STE Steris Plc | ▼ | $21.71B |
| SNN Smith & Nephew Plc | ▼ | $12.75B |
| ALGN Align Technology Inc | ▶ | $10.46B |
| MSA Msa Safety Inc | ▼ | $6.91B |
| ESTA Establishment Labs Holdings Inc. | ▲ | $1.76B |
| ENOV Enovis Corp | ▶ | $1.13B |
| CDRE Cadre Holdings, Inc. | ▼ | $1.13B |
| AVR Anteris Technologies Global Corp. | ▶ | $590M |
| SMTI Sanara Medtech Inc. | ▼ | $305M |
| INGN Inogen Inc | ▲ | $166M |
| LAKE Lakeland Industries Inc | ▲ | $90M |
| NTRB Nutriband Inc. | ▲ | $76M |
| APT Alpha Pro Tech Ltd | ▲ | $57M |
| COCH Envoy Medical, Inc. | ▼ | $52M |
| MYO Myomo, Inc. | ▲ | $48M |
| MLSS Milestone Scientific Inc. | ▲ | $29M |
| LFWD Lifeward Ltd. | ▲ | $17M |
| UEEC United Health Products, Inc. | ▲ | $14M |
| CUPR Cuprina Holdings (Cayman) Ltd | ▶ | $13M |
| RGNT Regentis Biomaterials Ltd. | ▶ | $10M |
| CLGN Collplant Biotechnologies Ltd | ▶ | $7M |
| LGMK Logicmark, Inc. | ▲ | $1M |
| BBLG Bone Biologics Corp | ▲ | $1M |
| RBOT Vicarious Surgical Inc. | ▼ | $550K |
| FEED Envue Medical, Inc. | ▼ | $340K |
Where ZBH sits on the market map
Zimmer Biomet Holdings, Inc. (ZBH) stock news
Loading...
Zimmer Biomet Holdings, Inc. (ZBH) stock forecast FAQ
What is the Zimmer Biomet Holdings, Inc. (ZBH) stock forecast?
Our AI ranks Zimmer Biomet Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Zimmer Biomet Holdings, Inc. stock predictions?
For ZBH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 26.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Zimmer Biomet Holdings, Inc. forecasts updated?
Zimmer Biomet Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Zimmer Biomet Holdings, Inc.'s industry peers?
27 issuers in our coverage, ZBH included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA), Establishment Labs Holdings Inc. (ESTA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.